Granules India (GRANULES) Fundamentals 2026 — P/E 31.6x, Revenue Analysis | SniperIQ
Granules India (GRANULES) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹21,074 Crore, trading at ₹851.80 on the BSE. This SniperIQ fundamentals page covers Granules India's valuation (P/E 31.6x, P/B 4.2x), profitability (net margin 11.8%), revenue (₹5,366 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Granules India's market cap?
Granules India (GRANULES) has a market capitalization of approximately ₹21,074 Crore, trading at ₹851.80 on the BSE. Market cap moves with the live share price.
What is Granules India's P/E ratio?
Granules India's trailing twelve-month P/E ratio is 31.6x, with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Granules India?
Granules India runs a net profit margin of 11.8%, a gross margin of 54.1%, and an operating margin of 17.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Granules India generate?
Granules India reported revenue of ₹5,366 Crore for fiscal year 2026, with net income of ₹595 Crore and earnings per share (EPS) of 24.47. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Granules India pay a dividend?
Granules India offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Granules India financially healthy?
Granules India carries a debt-to-equity ratio of 0.30x and a current ratio of 1.80x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Granules India a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Granules India (GRANULES) the key facts are: market cap ₹21,074 Crore, P/E 31.6x, revenue ₹5,366 Crore, 52-week range 412.05-885.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Granules India's full fundamentals live
Get Granules India's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.